(63 days)
Not Found
No
The description focuses on the mechanical action of the device (eccentrically rotating sanding surface) and does not mention any computational or data-driven components indicative of AI/ML. The performance studies are bench tests evaluating mechanical properties.
Yes
The device is indicated for use "as therapy in patients with occlusive atherosclerotic disease in peripheral arteries" and "as a therapy in patients with occluded hemodialysis grafts." It also "provides a method of removing stenotic material" to treat peripheral arteries and A-V graft stenosis.
No
Explanation: The device is described as a "peripheral orbital atherectomy system" used for removing stenotic material from arteries and grafts. Its function involves therapy and removal of material, not diagnosis.
No
The device description explicitly lists multiple hardware components (Orbital Atherectomy Device, Guide Wire, Saline Infusion Pump, Atherectomy Lubricant) and the performance studies focus on bench testing of these physical components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Diamondback 360 Peripheral Orbital Atherectomy System is a surgical device used within the body (percutaneously) to physically remove blockages (stenotic material) from blood vessels and grafts. It is a therapeutic device, not a diagnostic one.
- Lack of Diagnostic Activity: The description focuses on the mechanical action of the device (eccentrically rotating sanding surface) and its components for performing this therapeutic procedure. There is no mention of analyzing biological samples or providing diagnostic information.
Therefore, the Diamondback 360 Peripheral Orbital Atherectomy System is a therapeutic medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Diamondback 360 Peripheral Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The OAS supports removal of stenotic material from artificial arteriovenous dialysis fistulae (AV shunt). The OAS is a percutaneous orbital atherectorny system indicated as a therapy in patients with occluded hemodialysis grafts who are acceptable candidates for percutaneous transluminal angioplasty.
Product codes
MCW
Device Description
The Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is intended for use in the treatment of peripheral arteries and A-V graft (shunt) stenosis.
The OAS provides a method of removing stenotic material from peripheral arteries and A-V grafts. The Diamondback 360 uses an eccentrically rotating sanding surface (crown) to remove stenotic material on the vessel wall. The stenotic particles that are removed are small enough to be absorbed by the body.
The Diamondback 360 Peripheral Orbital Atherectomy System consists of the following components:
-
- Orbital Atherectomy Device (OAD)
-
- Atherectomy Guide Wire (e.g., ViperWire Advance)
-
- Saline Infusion Pump (SIP)
-
- Atherectomy Lubricant (e.g., ViperSlide)
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
peripheral arteries and A-V graft (shunt)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The Diamondback 360 Peripheral Orbital Atherectomy System was evaluated using the following performance bench testing to confirm the performance characteristics as compared to the predicate device.
- System Life Testing including guide wire .
- Stall Testing .
- Introducer Compatibility Testing .
- . Contrast Injection Testing
- . Temperature Testing
- Tensile Testing .
- . Flexibility Testing
- Delivered Torque Testing .
- Orbit Testing .
- . Flow Testing
- Track Testing .
- Packaging/Simulated Distribution Testing ●
All test results demonstrate that the materials chosen, the manufacturing process, and the design utilized for the Diamondback 360 Peripheral Orbital Atherectomy System met the established specifications necessary for consistent performance during its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K110389, K122987, K131092, K133399
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.4875 Intraluminal artery stripper.
(a)
Identification. An intraluminal artery stripper is a device used to perform an endarterectomy (removal of plaque deposits from arterisclerotic arteries.)(b)
Classification. Class II (performance standards).
0
FEB 2 8 2014
、ど
K133999 p. 1 of 3
| Section. 6 | 510(k) Summary |
|---|---|
| ------------ | ---------------- |
| Company Name: | Cardiovascular Systems, Inc.
651 Campus Drive
Saint Paul, MN 55112 | | |
|----------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|--|
| Contact: | Blair Buth | | |
| Phone: | (651) 259-2032 | | |
| Fax: | (651) 305-7734 | | |
| Summary Date: | February 28, 2014 | | |
| Trade Name: | Diamondback 360® Peripheral Orbital Atherectomy System | | |
| Product Code: | MCW—Catheter, Peripheral, Atherectomy | | |
| Classification Regulation: | 21 CFR 870.4875—Intraluminal Artery Stripper | | |
| Classification: | II | | |
| Predicate Devices: | | | |
| | 510(k) Numbers:
Manufacturer:
Trade Name: | K110389, K122987, & K131092
Cardiovascular Systems, Inc.
Stealth 360® Orbital PAD System, Model PRD-
SC30-125 | |
| | 510(k) Number:
Manufacturer:
Trade Name: | K133399
Cardiovascular Systems, Inc.
Diamondback 360® Peripheral Orbital
Atherectomy System, Model DBP-125MICRO145 | |
Description of Device 6.1
The Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is intended for use in the treatment of peripheral arteries and A-V graft (shunt) stenosis.
The OAS provides a method of removing stenotic material from peripheral arteries and A-V grafts. The Diamondback 360 uses an eccentrically rotating sanding surface (crown) to remove stenotic material on the vessel wall. The stenotic particles that are removed are small enough to be absorbed by the body.
1
K133999 p. 2 of 3
The Diamondback 360 Peripheral Orbital Atherectomy System consists of the following components:
-
- Orbital Atherectomy Device (OAD)
-
- Atherectomy Guide Wire (e.g., ViperWire Advance)
-
- Saline Infusion Pump (SIP)
-
- Atherectomy Lubricant (e.g., ViperSlide)
6.2 Description of Change
The Diamondback 360 Peripheral 60cm Orbital Atherectomy Device overall length was decreased to 60 centimeters (cm). The OAD driveshaft, saline sheath, and nosecone cap were modified to accommodate the shorter length. The updated OAD will be available in a 1.25 Micro and 1.25 Solid crown configuration. The 1.25 Micro OAD crown remains unchanged and the 1.25 Solid OAD crown was modified for compatibility with the smaller diameter drive shaft. The Diamondback 360 Peripheral 60cm OAD requires use of a smaller ViperWire Advance Atherectomy Guide Wire (0.012").
6.3 Intended Use
The Diamondback 360 Peripheral Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The OAS supports removal of stenotic material from artificial arteriovenous dialysis fistulae (AV shunt). The OAS is a percutaneous orbital atherectorny system indicated as a therapy in patients with occluded hemodialysis grafts who are acceptable candidates for percutaneous transluminal angioplasty.
6.4 Technology
The Diamondback 360 Peripheral Orbital Atherectomy System provides a method of removing or reducing occlusive atherosclerotic or stenotic material. The OAS applies a diamond coated, eccentrically rotating sanding surface to remove stenotic material on the vessel wall. The stenotic particles that are removed are small enough to be absorbed by the body. This is the same technology that was cleared to market for use in the peripheral arteries for Stealth 360° in 510(k) K110389, K122987, K131092 and for Diamondback 360° Peripheral per K133399.
6.5 Performance Data
The Diamondback 360 Peripheral Orbital Atherectomy System was evaluated using the following performance bench testing to confirm the performance characteristics as compared to the predicate device.
- System Life Testing including guide wire .
- Stall Testing .
- Introducer Compatibility Testing .
- . Contrast Injection Testing
2
- . Temperature Testing
- Tensile Testing .
- . Flexibility Testing
- Delivered Torque Testing .
- Orbit Testing .
- . Flow Testing
- Track Testing .
- Packaging/Simulated Distribution Testing ●
All test results demonstrate that the materials chosen, the manufacturing process, and the design utilized for the Diamondback 360 Peripheral Orbital Atherectomy System met the established specifications necessary for consistent performance during its intended use.
6.6 Conclusions
The Diamondback 360 Peripheral Orbital Atherectomy System met all predetermined acceptance criteria of design verification and validation testing as specified by applicable standards, test protocols, and/or customer inputs. Testing results demonstrate that the Diamondback 360 Peripheral Orbital Atherectomy System is substantially equivalent to the legally marketed predicate devices and does not raise any new safety or effectiveness questions.
3
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" arranged in a circular pattern around the symbol. The caduceus is a common symbol associated with healthcare and medicine.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
February 28, 2014
Cardiovascular Systems, Inc. c/o Mr. Blair Buth Regulatory Affairs Manager 651 Campus Drive Saint Paul, MN 55112
Re: K133999
Trade/Device Name: Diamondback 360® Peripheral Orbital Atherectomy System Regulation Number: 21 CFR 870.4875 Regulation Name: Intraluminal Artery Stripper Regulatory Class: Class II Product Code: MCW Dated: January 30, 2014 Received: January 31, 2014
Dear Mr. Buth:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
4
Page 2 - Mr. Blair Buth
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours, Kent
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Image /page/5/Picture/1 description: The image shows the logo for Cardiovascular Systems, Inc. The logo consists of the letters "CSI" in a bold, sans-serif font, with a curved line underneath the letters. To the right of the letters is the text "CARDIOVASCULAR SYSTEMS, INC." in a smaller, sans-serif font. The logo is simple and professional, and it is likely used on the company's website, marketing materials, and other communications.
Indications for Use Statement Section. 5
510(k) Number: _K133999
Device Name: Diamondback 360° Peripheral Orbital Atherectomy System
Indications for Use:
The Diamondback 360 Peripheral Orbital Atherectomy System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.
The OAS supports removal of stenotic material from artificial arteriovenous dialysis fistulae (AV shunt). The OAS is a percutaneous orbital atherectorny system indicated as a therapy in patients with occluded hemodialysis grafts who are acceptable candidates for percutaneous transluminal angioplasty.
Prescription Use _ X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Image /page/5/Picture/12 description: The image shows the name "Kenneth J. Cavanaugh -S" in bold, black font. The name is written in a clear, legible typeface. The text is horizontally aligned and appears to be part of a document or label. The letters are evenly spaced, and the overall impression is professional and easy to read.
Cardiovascular Systems, Inc. (CSI)
Diamondback 360® Peripheral Orbital Atherectorny System